Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease

Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Steven, Coyne, Daniel
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936265/
https://www.ncbi.nlm.nih.gov/pubmed/18360604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936265/
https://www.ncbi.nlm.nih.gov/pubmed/18360604

Ejemplares similares